PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program - PDS B

PDS Biotechnology stock tanks as the company refocuses resources on its PDS0301 metastatic colorectal cancer program.

Raccontata dabenzinga.com